Safety Study of RCT2100 for People with Cystic Fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests a new type of medicine called RCT2100 (CFTR mRNA) for people with cystic fibrosis who cannot take currently available CFTR modulators. It aims to see if the treatment is safe and tolerable, and may help improve lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of cystic fibrosis.
- Your lung function (FEV1) should be between 50% and 100% of the normal average for your age, sex, and height.
- You are not eligible for CFTR modulator therapies because of your specific CF gene mutations, or you are eligible but cannot take them due to intolerance or other medical reasons.
- You have not used any CFTR modulator (e.g., Trikafta, Kalydeco) in the last 12 weeks.
- You have no advanced liver disease (like cirrhosis with high blood pressure in the liver) and your oxygen level on room air is at least 94%.
- You have not had a lung infection or flare-up requiring changes in treatment in the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
This early study tests an individualized approach (“theratyping”) to match your cystic fibrosis (CF) to the CFTR medicine that may work best for your specific genetic change. It may help find a more tailored treatment plan and see how your body responds, while using medicines that are already approved for some people with CF.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study tests an experimental inhalable medicine called ARCT-032 for people with cystic fibrosis who cannot take or benefit enough from current CFTR modulators. The goal is to see if it safely improves lung function and quality of life.
This trial tests a new inhaled medicine (BMD003) that delivers CFTR mRNA to help correct the genetic defect causing cystic fibrosis. It is for patients who are 12 years or older, have stable CF, and meet certain lung function and weight criteria.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.